Resources
45 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 1/26/2024 (updated 3/28/2024)
Posted 12/8/2023 (updated 3/28/2024)
This fact sheet from the Policy Center for Maternal Mental Health about AI/AN Maternal Mental Health provides information on the disparities American Indian and Alaskan Native (AI/AN) women experience including Maternal Death, Trauma: A Contributing Factor to Post-traumatic Stress Disorder (PTSD), Intimate Partner Violence (IPV), and Inequities and Systemic Racism Lead to Stress and Adverse Outcomes.
Posted 12/8/2023 (updated 3/28/2024)
During the White House Tribal Nations Summit, President Biden will sign a historic Executive Order on Reforming Federal Funding and Support for Tribal Nations to Better Embrace Our Trust Responsibilities and Promote the Next Era of Tribal Self Determination. This Executive Order demonstrates the Biden-Harris Administration’s respect for Tribal sovereignty, and commitment to ushering in the next era of Tribal self-determination by ensuring that Tribal Nations have greater autonomy over how they invest federal funding.
Posted 10/15/2023 (updated 3/27/2024)
The National Institute of Mental Health (NIMH) offers a range of information on mental health disorders on their website to help bring awareness. NIMH now has brochures and fact sheets available in Spanish.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.
Posted 4/26/2023 (updated 3/27/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the Behavioral Health Care Support grantees.
Posted 4/26/2023 (updated 3/27/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the MAT Access grantees.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.